Odisha News, Odisha Latest news, Odisha Daily - OrissaPOST
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
No Result
View All Result
OrissaPOST - Odisha Latest news, English Daily -
No Result
View All Result

Good News! 1 dose of Regeneron antibody cocktail can cut the risk of COVID-19 for up to 8 months

Indo-Asian News Services
Updated: November 9th, 2021, 14:10 IST
in Coronavirus, Feature, National
0
Share on FacebookShare on TwitterShare on WhatsAppShare on Linkedin

Regeneron Pharmaceuticals Inc.’s antibody cocktail cut the risk of contracting Covid-19 by 82% for up to eight months, according to a company-sponsored study that could pave the way for its broader use.

The monoclonal antibody cocktail, known as REGEN-COV, is available under an emergency use authorization in the U.S. to treat outpatients at risk of developing severe symptoms. It’s also allowed as a preventive therapy for certain people who aren’t fully vaccinated or who are immunocompromised, and have known or likely exposure to the virus.

Also Read

Fraud Risk

RBI asks banks to use DoT tool to curb cyber fraud

10 hours ago
Viral video

Viral shock: Groom slapped on stage, twist leaves everyone stunned

10 hours ago

The company has asked the US Food and Drug Administration to expand the authorization so the drug can be used to prevent infections, even when it’s given before a person has been exposed.

“These data add to the increasing body of evidence supporting use of REGEN-COV to prevent Covid-19 in uninfected individuals, which may be especially useful for the many immunocompromised people who do not respond adequately to vaccines and remain ‘prisoners of the pandemic,’” George Yancopoulos, president and chief scientific officer at Regeneron, said in a statement.

The field for Covid treatments is growing more crowded, with Merck & Co. and Pfizer Inc. developing pills that have shown promising results in patients early in the course of disease. While monoclonal antibodies like Regeneron’s were developed earlier in the pandemic and may be used before the virus takes hold, the pills — if authorized — would be more convenient to transport and administer.

Analysts earlier in the year questioned the long-term prospects of Covid-19 treatments as vaccination rates increased and the number of new infections slowed. Regeneron, along with other drugmakers that produce monoclonal antibodies that jump start the immune system’s fight against the virus, have pitched the preventive use of their drugs.

The approach could particularly benefit people with weakened immune systems who may not develop sufficient protection after vaccination and are at higher risk of breakthrough infections, thereby fueling long-term demand.

The late-stage study, jointly run with the National Institute of Allergy and Infectious Diseases, enrolled people who lived in a household with someone diagnosed with Covid within the previous four days. Earlier results from the trial showed the drug cut the risk of infection by 81% within the first month. The new data shows the protection was maintained, with an 82% reduction in symptomatic infections for as long as eight months after the therapy was administered.

During the study, none of the people in the treatment group were hospitalized due to Covid, compared with six people in the placebo group. No deaths stemming from Covid infection occurred in either group.

Participants were allowed to get vaccinated after the first month. Immunization rates were balanced between those given placebo and those given the actual treatment, with about one-third of participants in both groups getting at least one dose, according to Regeneron.

Tags: Antibody Cocktailcovid treatmentsPfizerRegeneronvaccine
ShareTweetSendShare
Suggest A Correction

Enter your email to get our daily news in your inbox.

 

OrissaPOST epaper Sunday POST OrissaPOST epaper

Click Here: Plastic Free Odisha

#MyPaperBagChallenge

Archit Mohapatra

December 12, 2019
#MyPaperBagChallenge

Archana Parida

December 12, 2019
#MyPaperBagChallenge

Sisirkumar Maharana

December 12, 2019
#MyPaperBagChallenge

Chinmay Kumar Routray

December 12, 2019
#MyPaperBagChallenge

Swarit Praharaj

December 12, 2019
#MyPaperBagChallenge

Manas Samanta

December 12, 2019
#MyPaperBagChallenge

Pitabas Tripathy

December 12, 2019
#MyPaperBagChallenge

Mrutyunjaya Behera

December 12, 2019
#MyPaperBagChallenge

Geetanjali Patro

December 12, 2019
#MyPaperBagChallenge

Sarmistha Nayak

December 12, 2019
#MyPaperBagChallenge

Diptiranjan Biswal

December 12, 2019
#MyPaperBagChallenge

Adweeti Bhattacharya

December 12, 2019
#MyPaperBagChallenge

Saishree Satyarupa

December 12, 2019
#MyPaperBagChallenge

Adrita Bhattacharya

December 12, 2019
#MyPaperBagChallenge

Spinoj Pattnaik

December 12, 2019
#MyPaperBagChallenge

Amritansh Mishra

December 12, 2019
#MyPaperBagChallenge

Ramakanta Sahoo

December 12, 2019
#MyPaperBagChallenge

Rajashree Manasa Mohanty

December 12, 2019
#MyPaperBagChallenge

Aishwarya Ranjan Mohanty

December 12, 2019
#MyPaperBagChallenge

Pragyan Priyambada

December 12, 2019
#MyPaperBagChallenge

Subhajyoti Mohanty

December 12, 2019
#MyPaperBagChallenge

Akriti Negi

December 12, 2019
#MyPaperBagChallenge

Pratik Kumar

December 12, 2019
#MyPaperBagChallenge

Subhajyoti Mohanty

December 12, 2019
#MyPaperBagChallenge

Ipsita

December 12, 2019
#MyPaperBagChallenge

Sipra Mishra

December 12, 2019
#MyPaperBagChallenge

Surya Sidhant Rath

December 12, 2019
#MyPaperBagChallenge

Parbati Mohanty

December 12, 2019
#MyPaperBagChallenge

D Rama Rao

December 12, 2019
#MyPaperBagChallenge

Akshaya Kumar Dash

December 12, 2019

Archives

Editorial

Hungary Lessons

Hungary
July 2, 2025

Revolting against oppression and seeking freedom is ingrained in human nature, something that a repressive regime finds out sooner or...

Read more

New Democratic Face

Zohran Mamdani
July 1, 2025

US President Donald Trump, who had comfortably defeated his Democratic rival Kamala Harris in the recent presidential election and exuded...

Read more

Proof To Vote

Vote
June 30, 2025

Months ahead of the Assembly polls in Bihar, the Election Commission of India (ECI) on 28 June launched a ‘special...

Read more

Genesis of Jana Sangh

AAKAR PATEL
June 29, 2025

We marked the 50th anniversary of the Emergency a few days ago. Another anniversary, this time the 75th, went relatively...

Read more
  • Home
  • State
  • Metro
  • National
  • International
  • Business
  • Editorial
  • Opinion
  • Sports
  • About Us
  • Advertise
  • Contact Us
  • Jobs
Developed By Ratna Technology

© 2024 All rights Reserved by OrissaPOST

  • News in Odia
  • Orissa POST Epaper
  • Video
  • Home
  • Trending
  • Metro
  • State
  • Odisha Special
  • National
  • International
  • Sports
  • Business
  • Editorial
  • Entertainment
  • Horoscope
  • Careers
  • Feature
  • Today’s Pic
  • Opinion
  • Sci-Tech
  • About Us
  • Contact Us
  • Jobs

© 2024 All rights Reserved by OrissaPOST

    • News in Odia
    • Orissa POST Epaper
    • Video
    • Home
    • Trending
    • Metro
    • State
    • Odisha Special
    • National
    • International
    • Sports
    • Business
    • Editorial
    • Entertainment
    • Horoscope
    • Careers
    • Feature
    • Today’s Pic
    • Opinion
    • Sci-Tech
    • About Us
    • Contact Us
    • Jobs

    © 2024 All rights Reserved by OrissaPOST